ADAMTS3 and central nervous system cancer: To validate ADAMTS3 expression levels in our cell lines, ADAMTS3 mRNA expression levels in NHA, glioma cell lines (A172, A1207, U87MG, and LN229), and patient‐derived GSCs (GSC11, 20, 23, and 267) were examined.